MBIO Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Mustang Bio's net margin of --. Mustang Bio's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 8447.01%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.2692 which suggests that it could grow by 350.13%. Given that Mustang Bio has higher upside potential than Perspective Therapeutics, analysts believe Mustang Bio is more attractive than Perspective Therapeutics.

Mustang Bio has a beta of 2.239, which suggesting that the stock is 123.909% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.093, suggesting its more volatile than the S&P 500 by 9.29%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Mustang Bio's net income of -$153K is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Mustang Bio's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 22.34x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Mustang Bio's net margin of 12.06%. Mustang Bio's return on equity of -- beat Electromed's return on equity of 16.57%.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 8447.01%. On the other hand Electromed has an analysts' consensus of $38.00 which suggests that it could grow by 89.34%. Given that Mustang Bio has higher upside potential than Electromed, analysts believe Mustang Bio is more attractive than Electromed.

Mustang Bio has a beta of 2.239, which suggesting that the stock is 123.909% more volatile than S&P 500. In comparison Electromed has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.159%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Electromed quarterly revenues of $15.7M. Mustang Bio's net income of -$153K is lower than Electromed's net income of $1.9M. Notably, Mustang Bio's price-to-earnings ratio is -- while Electromed's PE ratio is 25.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 2.93x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Mustang Bio's net margin of -35.79%. Mustang Bio's return on equity of -- beat Protalix BioTherapeutics's return on equity of 10.9%.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 8447.01%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 839.6%. Given that Mustang Bio has higher upside potential than Protalix BioTherapeutics, analysts believe Mustang Bio is more attractive than Protalix BioTherapeutics.

Mustang Bio has a beta of 2.239, which suggesting that the stock is 123.909% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.210, suggesting its less volatile than the S&P 500 by 120.951%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Mustang Bio's net income of -$153K is higher than Protalix BioTherapeutics's net income of -$3.6M. Notably, Mustang Bio's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 37.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 2.09x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Mustang Bio's net margin of 0.18%. Mustang Bio's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 8447.01%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 181.13%. Given that Mustang Bio has higher upside potential than Xtant Medical Holdings, analysts believe Mustang Bio is more attractive than Xtant Medical Holdings.

Mustang Bio has a beta of 2.239, which suggesting that the stock is 123.909% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Mustang Bio's net income of -$153K is lower than Xtant Medical Holdings's net income of $58K. Notably, Mustang Bio's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 0.70x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.